IOVA Q3 2020 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$59M

Net Income

-$59M

EPS (Diluted)

$-0.40

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$58M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$782M

Total Liabilities

$70M

Stockholders' Equity

$712M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$59M	-$52M	-14.3%
Net Income	-$59M	-$49M	-18.4%